The rise of Sildenafil initially drove a period of growth for pharma, nevertheless recent developments present a complicated picture for investors. Lower-cost competitors are eroding revenue, and persistent patent https://zaynabszjc102653.blogsvirals.com/39903075/the-blue-pill-and-pharma-a-volatile-bet